ARGX: H.C. Wainwright Remains Bullish
H.C. Wainwright remains bullish on Argenx despite changes to the Phase 3 Vyvgart study in myositis, citing strong prospects in immune-mediated necrotizing myopathy
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
ARGX: HC Wainwright Maintains Buy
argenx shares are trading higher after HC Wainwright & Co. maintained its Buy rating on the stock and reiterated its $940 price target.